Hypofractionated WBI Slow to Catch On
Despite having advantages over conventional whole breast irradiation, hypofractionated WBI is used by only a third of patients who would benefit.
FDA Approves New Drug for Advanced Ovarian Cancer
The FDA has approved olaparib, to be marketed under the name Lynparza, for the treatment of advanced ovarian cancer related to defective BRCA genes.
Should the Exit Age for Cervical Cancer Screening Be Extended?
The highest rates of cervical cancer occur in women aged 65 to 69, according to new estimates. This suggests that screening guidelines may need to be reconsidered.
HPV Vaccine Not Linked to Riskier Sexual Behaviors
The sexual behaviors and beliefs about HPV infection were unchanged among a group of teens and young women who were vaccinated against the virus, research shows.
Study Calls into Question Appropriate Age to Stop Cervical Cancer Screening
New evidence reveals that there may be a benefit to continuing cervical cancer screening beyond age 65 years.
New Evidence Shows Benefit to Screening Older Women for Cervical Cancer
Women whose cervical cancer screening ceased between ages 50 and 64 years were 6 times more likely than women who were screened to have cervical cancer from ages 65 to 83 years.
Women With CIN3 Need Continued Follow-Up Throughout Old Age
Diagnosis and treatment of high-grade cervical dysplasia substantially increases the risk of cervical or vaginal cancer at or after age 60 years, a study finds.
Cervical Cancer: Is a New Detection Method Coming?
A simple blood test using plasma thermogram could serve as an effective new indicator for detecting cervical cancer, including assessment of the cancer’s stage.
Cervical Cancer: Newly Discovered Gene Mutations May Lead to More Targeted Therapies
Researchers discovered 13 gene mutations of significance in cervical cancer, including 8 mutations not previously linked to cervical cancer and 2 mutations novel to any type of cancer.
AAGL 2013: Single-Port Surgery Feasible, Safe for Many Gynecologic Cancer Patients
The surgical outcomes of single port pelvic surgeries (SiPPS) for a variety of gynecologic oncology indications are similar to those of traditional laparoscopic techniques.